Home/Atommap/Arie Zask, PhD

AZ

Arie Zask, PhD

Head of Chemistry

Therapeutic Areas

Atommap Pipeline

Drug	Indication	Phase
Mutant KRAS Program	Oncology (KRAS-mutant cancers)	Pre-clinical
SMARCA2 Degrader Program	Oncology	Pre-clinical
Mutant-Selective Degrader Program	Oncology (unspecified mutant oncoprotein)	Pre-clinical

Leadership Team at Atommap

Huafeng Xu, PhD

Founder and CEO

Jesus Izaguirre, PhD

Co-founder and Chief Computational Scientist

Co-founder and Chief Technology Officer

Cheryl Koh, PhD

Head of Discovery Biology

Mandana Honu, PhD

Head of Business Development

View full Atommap profile